%0 Journal Article
%T HER-2 directed therapies across gastrointestinal tract cancers - A new frontier.
%A Jones L
%A Cunningham D
%A Starling N
%J Cancer Treat Rev
%V 129
%N 0
%D 2024 Jun 21
%M 38959629
%F 13.608
%R 10.1016/j.ctrv.2024.102789
%X Gastrointestinal (GI) cancers are common and in the metastatic setting they have a poor prognosis. The current mainstay of treatment of GI cancers is chemotherapy; however, the biomarker-directed treatment landscape is evolving. HER-2 is overexpressed in a portion of GI cancers and is an emerging target for therapy, with recent FDA tumor agnostic approval for trastuzumab deruxtecan. Testing for HER-2 expression is not standardized across GI cancers, methodology requires further optimization and standardization as HER-2 targeted therapy emerges into the treatment landscape. There is established rationale for use of HER-2 targeted therapy in first line treatment of metastatic gastric cancer, and emerging evidence with variable benefit in bile duct, pancreatic and colorectal cancers.